Medical Weight Loss Clinic Bangkok — Doctor-Led GLP-1 Programs

A physician-supervised program combining medical intake, contraindication screening, baseline biomarkers, a prescribed GLP-1 medication (Mounjaro, Wegovy or Retatrutide) and monthly follow-up. It is doctor-led, not a cosmetic or over-the-counter service.

There is no single best option. Mounjaro is a dual GIP/GLP-1 agonist approved for type 2 diabetes and weight management. Wegovy is a GLP-1 agonist approved for weight management. Retatrutide is investigational. The physician selects based on indications, contraindications and biomarker profile.

Mounjaro and Wegovy are prescription medicines and must be initiated by a licensed physician. Retatrutide is investigational and is offered only under physician supervision in a research framework. They cannot be sold over the counter.

Most guests follow a 3 to 12 month physician-supervised program, with monthly follow-up. Duration is individualized based on clinical goals, tolerability, biomarker trends and the broader longevity plan.

The most reported effects are nausea, diarrhea, decreased appetite, vomiting and constipation, typically during titration. Rare but serious risks include pancreatitis and gallbladder disease. Every program includes monthly side-effect review.

Yes. HbA1c, lipid panel, hepatic and renal function are established before the first dose. For Retatrutide, an extended panel is added. Follow-up labs are reviewed at every monthly visit.

Yes. GLP-1 medicines such as Mounjaro and Wegovy are legal in Thailand when prescribed by a licensed physician, with no residency or long-term visa required. Expats and short-stay visitors are equally welcome at Healthi Life Ekkamai — your program starts with an in-clinic physician consultation and baseline labs, and monthly follow-up can continue by telemedicine once you have travelled home, so dosing stays monitored.

GLP-1 medicines are temperature-sensitive and must be kept cold. After in-clinic injection training, your physician advises on safe cold-chain transport, self-injection and titration for the weeks between visits. Retatrutide, being investigational, is administered within a supervised research framework and is not dispensed for unsupervised long-term travel.